Merck tops quarterly estimates, posts modest 2026 guidance as generic competition looms [MSNBC.com]
Merck & Company, Inc. (new) (MRK)
Last merck & company, inc. (new) earnings: 4/28 06:45 am
Check Earnings Report
US:NYSE Investor Relations:
investors.merck.com/home/default.aspx
Company Research
Source: MSNBC.com
In this articleDado Ruvic | ReutersMerckBut the company posted a modest 2026 outlook that fell short of Wall Street's expectations as it prepares for a few drugs to lose patent protection later this year and face generic competition. That includes Type 2 diabetes drugs, Januvia and Janumet, and Bridion, a treatment that helps restore muscle function that was blocked during surgery.While those medicines aren't top-selling products like Keytruda, their combined lower sales will likely pressure the company.The pharmaceutical giant anticipates its 2026 revenue will come in between $65.5 billion and $67 billion. Analysts expected revenue of $67.6 billion, according to LSEG.Merck also expects adjusted earnings to come in between $5 and $5.15 per share. That compares to analysts' estimate of $5.36 per share, according to LSEG.That range includes a one-time charge of roughly $9 billion, or around $3.65 per share, related to Merck's acquisition of Cidara, a biotech company that is developing
Show less
Read more
Impact Snapshot
Event Time:
MRK
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MRK alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MRK alerts
High impacting Merck & Company, Inc. (new) news events
Weekly update
A roundup of the hottest topics
MRK
News
- Merck and Pfizer decline vs the broader market as results released [Yahoo! Finance]Yahoo! Finance
- Merck's (NYSE:MRK) Q4 CY2025 Sales Beat Estimates [Yahoo! Finance]Yahoo! Finance
- China NMPA Approves Promega MSI Detection Kit as Companion Diagnostic for KEYTRUDA® [Yahoo! Finance]Yahoo! Finance
- Earnings Snapshot: Merck tops Q4, issues weaker-than-expected FY profit and sales outlook [Seeking Alpha]Seeking Alpha
- Merck in Charts: Q4 sees pharmaceutical sales up ~6% Y/Y, led by 7% rise in KEYTRUDA [Seeking Alpha]Seeking Alpha
MRK
Earnings
- 2/3/26 - Beat
MRK
Sec Filings
- 2/3/26 - Form 8-K
- 1/28/26 - Form 4
- 1/28/26 - Form 4
- MRK's page on the SEC website